What is LUCA Science?
LUCA Science operates at the intersection of biotechnology and regenerative medicine, specifically targeting the mitochondria as a therapeutic focal point. By developing proprietary technologies to isolate and deliver functional mitochondria, the company aims to restore cellular energy metabolism in patients suffering from degenerative conditions. As a pre-clinical stage organization, LUCA Science occupies a critical niche in the Japanese life sciences ecosystem, leveraging advanced manufacturing and biological engineering to translate fundamental mitochondrial research into viable clinical candidates. Its market position is bolstered by a diverse syndicate of international and domestic backers who recognize the transformative potential of mitochondrial-based interventions in modern medicine.
How much funding has LUCA Science raised?
LUCA Science has raised a total of $40.1M across 2 funding rounds:
Series A
$9.8M
Series B
$30.3M
Series A (2020): $9.8M with participation from Axil Capital Advisors KK/ Axil Capital Partners
Series B (2022): $30.3M led by DCI WALBRIDGE PARTNERS, Nissay Capital, SMBC Venture Capital, Fast Track, Asahi Kasei Pharma America (AKP America), QB Capital/NCB Venture Capital, and 4BIO Capital
Key Investors in LUCA Science
DCI WALBRIDGE PARTNERS
A joint-venture between the Walbridge Group and Delta Capital Investment, this firm focuses on manufacturing, engineering, and real estate, bringing industrial expertise to its investment portfolio.
Nissay Capital
A Japan-based global management and financial consulting firm that provides strategic support and capital to companies navigating complex industry disruptions.
4BIO Capital
A London-based venture capital firm specializing in life sciences, with a specific focus on advanced therapies including gene, cell, and RNA-based treatments.
What's next for LUCA Science?
With the recent influx of capital, LUCA Science is poised to transition its lead programs toward clinical readiness. The strategic roadmap likely involves scaling its manufacturing capabilities to ensure the stability and purity of mitochondrial preparations, alongside expanding its pre-clinical data sets to support future regulatory filings. By focusing on high-impact therapeutic areas, the company is well-positioned to navigate the complexities of the biopharmaceutical landscape, potentially attracting further partnerships or strategic alliances as it moves closer to human trials. The emphasis remains on validating the safety and efficacy of its platform, ensuring that the firm remains at the forefront of the emerging mitochondrial medicine sector.
See full LUCA Science company page
